AMRX stock news today

Amneal Pharmaceuticals holds Q3 2026 earnings call

Amneal Pharmaceuticals discussed its third-quarter 2026 results on an earnings call. The headline gives no figures or details from the quarter.

Amneal Pharmaceuticals releases Q3 2026 earnings, boosts yearly outlook

Amneal Pharmaceuticals published its quarterly numbers for the period ended in 2026 and lifted its forecast for the entire year. Specific figures were not included in the headline.

Amneal Pharmaceuticals lifts FY2026 adjusted EPS and sales guidance

Amneal Pharmaceuticals increased its fiscal 2026 adjusted earnings per share outlook to $1.04-$1.08 from $0.96-$1.06, and raised its sales forecast to $3.150B-$3.250B from $3.100B-$3.200B. Both new ranges sit above or near analyst estimates.

Amneal third-quarter adjusted profit tops estimate at $0.26 per share

The drugmaker's quarterly adjusted earnings came in above analyst expectations. Revenue of $862.684 million also exceeded the $816.058 million forecast.

Goldman Sachs kept its Buy rating on Amneal (AMRX) and raised its price target to $24 from $21.

Amneal Pharmaceuticals boosts estradiol patch output as demand climbs

Amneal Pharmaceuticals is raising production of its estradiol patch in response to growing demand. The move expands supply of the company's hormone therapy product.

Trump administration drops opioid ban plan after kratom industry lobbying

The administration reversed course on a proposed opioid ban following lobbying from the kratom industry. The decision means kratom remains available under current rules.

Matthew Cascio leaves Amneal Pharmaceuticals to join Laxxon Medical

Matthew Cascio has departed Amneal Pharmaceuticals and moved to Laxxon Medical. The change involves a leadership shift at both companies.

Analyst Lifts Amneal Stock Objective to $24

A research analyst increased the projected value for Amneal Pharmaceuticals shares to $24.00. The change reflects updated expectations for the drugmaker.

JP Morgan keeps Overweight rating on Amneal Pharmaceuticals, lifts target to $24

JP Morgan reiterated its Overweight rating on Amneal Pharmaceuticals and increased its price target to $24. The change reflects the firm's updated view on the stock.

Oppenheimer starts Amneal Pharmaceuticals coverage with Outperform rating, $27 target

Oppenheimer began covering Amneal Pharmaceuticals and gave the stock an Outperform rating. The firm set a price target of $27 per share.

Barclays keeps Overweight rating on Amneal Pharmaceuticals, lifts target to $20

Barclays reiterated its Overweight rating on Amneal Pharmaceuticals and raised its price target to $20. The update reflects the analyst's revised expectations for the drugmaker.

Leerink Partners starts Amneal Pharmaceuticals at Outperform, $23 target

Leerink Partners began covering Amneal Pharmaceuticals with an Outperform rating and set a $23 price target on the stock.

Amneal Pharmaceuticals registers resale of as many as 28,942,098 Class A shares held by selling stockholders

Amneal Pharmaceuticals filed a prospectus covering a resale program in which selling stockholders may offer as many as 28,942,098 Class A common shares. The document registers that potential share transfer.

JP Morgan restarts Amneal Pharmaceuticals coverage with Overweight rating, $22 target

JP Morgan resumed covering Amneal Pharmaceuticals with an Overweight rating and set a $22 price target on the shares.

What is the latest news on AMRX?

Nov 3, 2026: Amneal Pharmaceuticals holds Q3 2026 earnings call (Benzinga) · Nov 3, 2026: Amneal Pharmaceuticals releases Q3 2026 earnings, boosts yearly outlook (Fiscal.ai) · Nov 3, 2026: Amneal Pharmaceuticals lifts FY2026 adjusted EPS and sales guidance (Benzinga)

What are analysts saying about AMRX?

Oct 29, 2026: Goldman Sachs kept its Buy rating on Amneal (AMRX) and raised its price target to $24 from $21.